FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123380862> ?p ?o ?g. }

• W3123380862 endingPage "918" @default.
• W3123380862 startingPage "908" @default.
• W3123380862 abstract "Abstract Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Previous population pharmacokinetic (PK) models have been developed in solid organ transplant, yet none exists for patients receiving HCT. The primary objectives of this study were to (1) use a previously published population PK model in adult patients who underwent kidney transplant and apply it to allogeneic HCT; (2) evaluate model‐predicted tacrolimus steady‐state trough concentrations and simulations in patients receiving HCT; and (3) evaluate covariates that affect tacrolimus PK in allogeneic HCT. A total of 252 adult patients receiving allogeneic HCT were included in the study. They received oral tacrolimus twice daily (0.03 mg/kg) starting 3 days prior to transplant. Data for these analyses included baseline clinical and demographic data, genotype data for single nucleotide polymorphisms in CYP3A4 / 5 and ABCB1 , and the first tacrolimus steady‐state trough concentration. A dosing simulation strategy based on observed trough concentrations (rather than model‐based predictions) resulted in 12% more patients successfully achieving tacrolimus trough concentrations within the institutional target range (5–10 ng/ml). Stepwise covariate analyses identified HLA match and conditioning regimen (myeloablative vs. reduced intensity) as significant covariates. Ultimately, a previously published tacrolimus population PK model in kidney transplant provided a platform to help establish a model‐based dose adjustment strategy in patients receiving allogenic HCT, and identified HCT‐specific covariates to be considered for future prospective studies. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Tacrolimus is a cornerstone immunosuppressant used in patients who undergo organ transplantations. However, because of its narrow therapeutic index and wide interpatient pharmacokinetic (PK) variability, optimizing its dose is crucial to maximize efficacy and minimize tacrolimus‐induced toxicities. Prior to this study, no tacrolimus population PK models have been developed for adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Therefore, research effort was warranted to develop a population PK model that begins to propose more precision tacrolimus dosing and begins to address both a clinical and scientific gap in this patient population. WHAT QUESTION DID THIS STUDY ADDRESS? The study addressed whether there is value in utilizing the observed tacrolimus steady‐state trough concentrations from patients receiving allogeneic HCT within the context of a pre‐existing population PK model developed for kidney transplant. The study also addressed whether there are clinically relevant covariates specific to adult patients receiving allogeneic HCT. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Inclusion of a single steady‐state tacrolimus trough concentration is beneficial to model predictions. The dosing simulation strategy based on observed tacrolimus concentration, rather than the model‐predicted concentration, resulted in more patients achieving the target range at first steady‐state collection. Future studies should evaluate HLA matching and myeloablative conditioning versus reduced intensity conditioning regimens as covariates. These data and model‐informed dose adjustments should be included in future prospective studies. This research could also serve as a template as to how to assess the utility of prior information for other disease settings. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? The M2 model fitting method and D2 dosing simulation method can be applied to other clinical pharmacology studies where only a single steady‐state trough concentration is available per patient in the presence of a previously published population PK model." @default.
• W3123380862 created "2021-02-01" @default.
• W3123380862 creator A5012352119 @default.
• W3123380862 creator A5012898397 @default.
• W3123380862 creator A5016015982 @default.
• W3123380862 creator A5026490198 @default.
• W3123380862 creator A5040069705 @default.
• W3123380862 creator A5040689925 @default.
• W3123380862 creator A5042956546 @default.
• W3123380862 creator A5060988862 @default.
• W3123380862 creator A5063045360 @default.
• W3123380862 creator A5073215677 @default.
• W3123380862 creator A5079183709 @default.
• W3123380862 creator A5087335717 @default.
• W3123380862 creator A5089325052 @default.
• W3123380862 date "2021-01-27" @default.
• W3123380862 modified "2023-10-17" @default.
• W3123380862 title "Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients" @default.
• W3123380862 cites W1436442583 @default.
• W3123380862 cites W1592567691 @default.
• W3123380862 cites W1599272508 @default.
• W3123380862 cites W1913100467 @default.
• W3123380862 cites W1967670996 @default.
• W3123380862 cites W1987997716 @default.
• W3123380862 cites W1994909423 @default.
• W3123380862 cites W2005891936 @default.
• W3123380862 cites W2017893940 @default.
• W3123380862 cites W2033139608 @default.
• W3123380862 cites W2038989721 @default.
• W3123380862 cites W2068650301 @default.
• W3123380862 cites W2070458935 @default.
• W3123380862 cites W2081858766 @default.
• W3123380862 cites W2088804964 @default.
• W3123380862 cites W2097902267 @default.
• W3123380862 cites W2099937170 @default.
• W3123380862 cites W2125525909 @default.
• W3123380862 cites W2144535667 @default.
• W3123380862 cites W2150965753 @default.
• W3123380862 cites W2158282974 @default.
• W3123380862 cites W2178522631 @default.
• W3123380862 cites W2234054426 @default.
• W3123380862 cites W2314373344 @default.
• W3123380862 cites W2330631272 @default.
• W3123380862 cites W2341274521 @default.
• W3123380862 cites W2410226431 @default.
• W3123380862 cites W2622063078 @default.
• W3123380862 cites W2622965712 @default.
• W3123380862 cites W2755899935 @default.
• W3123380862 cites W2757354840 @default.
• W3123380862 cites W2804842286 @default.
• W3123380862 cites W2884628875 @default.
• W3123380862 cites W2900771606 @default.
• W3123380862 cites W2903405155 @default.
• W3123380862 cites W2905118355 @default.
• W3123380862 cites W2907796455 @default.
• W3123380862 cites W2942673049 @default.
• W3123380862 cites W2977041996 @default.
• W3123380862 cites W2990707203 @default.
• W3123380862 cites W3003959691 @default.
• W3123380862 cites W4366461198 @default.
• W3123380862 doi "https://doi.org/10.1111/cts.12956" @default.
• W3123380862 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8212733" @default.
• W3123380862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33502111" @default.
• W3123380862 hasPublicationYear "2021" @default.
• W3123380862 type Work @default.
• W3123380862 sameAs 3123380862 @default.
• W3123380862 citedByCount "4" @default.
• W3123380862 countsByYear W31233808622021 @default.
• W3123380862 countsByYear W31233808622022 @default.
• W3123380862 crossrefType "journal-article" @default.
• W3123380862 hasAuthorship W3123380862A5012352119 @default.
• W3123380862 hasAuthorship W3123380862A5012898397 @default.
• W3123380862 hasAuthorship W3123380862A5016015982 @default.
• W3123380862 hasAuthorship W3123380862A5026490198 @default.
• W3123380862 hasAuthorship W3123380862A5040069705 @default.
• W3123380862 hasAuthorship W3123380862A5040689925 @default.
• W3123380862 hasAuthorship W3123380862A5042956546 @default.
• W3123380862 hasAuthorship W3123380862A5060988862 @default.
• W3123380862 hasAuthorship W3123380862A5063045360 @default.
• W3123380862 hasAuthorship W3123380862A5073215677 @default.
• W3123380862 hasAuthorship W3123380862A5079183709 @default.
• W3123380862 hasAuthorship W3123380862A5087335717 @default.
• W3123380862 hasAuthorship W3123380862A5089325052 @default.
• W3123380862 hasBestOaLocation W31233808621 @default.
• W3123380862 hasConcept C112705442 @default.
• W3123380862 hasConcept C126322002 @default.
• W3123380862 hasConcept C128057223 @default.
• W3123380862 hasConcept C2777288759 @default.
• W3123380862 hasConcept C2777408962 @default.
• W3123380862 hasConcept C2908647359 @default.
• W3123380862 hasConcept C2909675724 @default.
• W3123380862 hasConcept C2910800852 @default.
• W3123380862 hasConcept C2911091166 @default.
• W3123380862 hasConcept C31785415 @default.
• W3123380862 hasConcept C71924100 @default.
• W3123380862 hasConcept C98274493 @default.
• W3123380862 hasConcept C99454951 @default.
• W3123380862 hasConceptScore W3123380862C112705442 @default.

• next